Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease

Prothena moves forward with layoffs; Aldeyra resubmits dry eye drug to FDA

Plus, news about Ventyx Biosciences, Gilead Sciences, Insilico Medicine and Enliven Therapeutics: Prothena lays off 91 workers: The company previously disclosed plans for a "substantial" workforce reduction after it stopped development of ...

Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease

The company believes results from a recent phase 3 chamber trial fulfill the FDA’s requests in the Complete Response Letter received in April of 2025.

Aldeyra Resubmits Reproxalap NDA for the Treatment of Dry Eye Disease

Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint. “Consistent with a number of clinical trials that suggest the potential of reproxalap to rapidly …